Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging With Quantitative Biochemical Measures of Aβ42 but not Aβ40

Manuscript Number: 

17-0762R2

Author(s): 
Thomas G. Beach, Anthony Intorcia, Abhinay D. Joshi, Ming Lu, Chera L. Maarouf, Michael J. Pontecorvo, Alex E. Roher, Geidy Serrano, Lucia I. Sue

Disclosures

Thomas G. Beach

  • Consulting Fees:
    Consulting fees from Genentech, Prothena, GSK and Roche.
    Grants
    • Agency: 
      Navidea Biopharmaceuticals
      Dates: 
      Current
    • Agency: 
      Avid Radiopharmaceuticals
      Dates: 
      current

Anthony Intorcia

  • Nothing to Disclose

Abhinay D. Joshi

  • Sponsors:
    Avid Radiopharmaceuticals Inc.

Ming Lu

  • Nothing to Disclose

Chera L. Maarouf

  • Nothing to Disclose

Michael J. Pontecorvo

  • Equity:
    Stockholder Eli Lilly (<$250,000) Stockholder Johnson and Johnson (<$250,000) General Electric (<$20,000)
    Sponsors:
    Vice President, Clinical Development Research

Alex E. Roher

  • Nothing to Disclose

Geidy Serrano

  • Nothing to Disclose

Lucia I. Sue

  • Nothing to Disclose